The superexacerbator phenotype in patients with COPD: a descriptive analysis.
作者信息
Vanfleteren Lowie E G W, Boonen Lotte M C, Spruit Martijn A, Janssen Daisy J A, Wouters Emiel F M, Franssen Frits M E
机构信息
CIRO, Horn, The Netherlands.
COPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
出版信息
ERJ Open Res. 2019 Jun 4;5(2). doi: 10.1183/23120541.00235-2018. eCollection 2019 Apr.
Abstract
摘要
相似文献
1
The superexacerbator phenotype in patients with COPD: a descriptive analysis.
ERJ Open Res. 2019 Jun 4;5(2). doi: 10.1183/23120541.00235-2018. eCollection 2019 Apr.
2
Pulmonary rehabilitation referral and uptake from primary care for people living with COPD: a mixed-methods study.慢性阻塞性肺疾病患者从初级保健机构获得肺康复转诊及接受情况：一项混合方法研究
ERJ Open Res. 2020 Feb 17;6(1). doi: 10.1183/23120541.00219-2019. eCollection 2020 Jan.
3
A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations.对慢性阻塞性肺疾病（COPD）加重期管理的随机对照试验中所使用的COPD及其加重期诊断标准的系统评价。
ERJ Open Res. 2019 Nov 15;5(4). doi: 10.1183/23120541.00136-2019. eCollection 2019 Oct.
4
Interleukin 33: a suitable target for biological therapies of COPD?白细胞介素33：慢性阻塞性肺疾病生物治疗的合适靶点？
ERJ Open Res. 2024 Sep 23;10(5). doi: 10.1183/23120541.00433-2024. eCollection 2024 Sep.
5
Pneumonia in exacerbations of COPD: what is the clinical significance?慢性阻塞性肺疾病急性加重期的肺炎：其临床意义是什么？
ERJ Open Res. 2020 Jan 27;6(1). doi: 10.1183/23120541.00282-2019. eCollection 2020 Jan.
6
Thoughts on medical oxygen, COPD and enjoying life.
Breathe (Sheff). 2019 Sep;15(3):171-172. doi: 10.1183/20734735.0208-2019.
7
Pubertal-onset overweight and COPD in men: a cohort study.男性青春期开始时超重与慢性阻塞性肺疾病：一项队列研究。
ERJ Open Res. 2020 Mar 2;6(1). doi: 10.1183/23120541.00326-2019. eCollection 2020 Jan.
8
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?我们能否使用生物标志物来指导重度慢性阻塞性肺疾病急性加重期的抗生素治疗？
Breathe (Sheff). 2019 Dec;15(4):353-355. doi: 10.1183/20734735.0257-2019.
9
Women with COPD.患有慢性阻塞性肺疾病的女性。
Breathe (Sheff). 2020 Dec;16(4):200239. doi: 10.1183/20734735.0239-2020.
10
Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness.芬太尼鼻喷雾剂用于一名终末期慢性阻塞性肺疾病（COPD）且伴有严重慢性呼吸困难的患者。
Breathe (Sheff). 2019 Sep;15(3):e122-e125. doi: 10.1183/20734735.0183-2019.
引用本文的文献
1
Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015-2019).接受吸入三联疗法时发生急性加重的慢性阻塞性肺疾病患者的特征和结局：美国SIRIUS I队列研究（2015 - 2019年）的结果
Int J Chron Obstruct Pulmon Dis. 2025 Jun 11;20:1851-1864. doi: 10.2147/COPD.S513573. eCollection 2025.
2
Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts' review.单吸入器三联疗法在阻塞性气道疾病管理中的应用：印度医学专家综述
ERJ Open Res. 2022 Mar 28;8(1). doi: 10.1183/23120541.00556-2021. eCollection 2022 Jan.
本文引用的文献
1
Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.慢性阻塞性肺疾病患者的加重频率：SPIROMICS 队列分析。
Lancet Respir Med. 2017 Aug;5(8):619-626. doi: 10.1016/S2213-2600(17)30207-2. Epub 2017 Jun 28.
2
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.全球慢性阻塞性肺疾病诊断、管理和预防策略 2017 年报告：GOLD 执行摘要。
Eur Respir J. 2017 Mar 6;49(3). doi: 10.1183/13993003.00214-2017. Print 2017 Mar.
3
How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?双长效支气管扩张剂如何预防慢性阻塞性肺疾病恶化？
Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI.
4
Rising total costs and mortality rates associated with admissions due to COPD exacerbations.慢性阻塞性肺疾病急性加重导致的住院相关总费用和死亡率不断上升。
Respir Res. 2016 Nov 14;17(1):149. doi: 10.1186/s12931-016-0469-6.
5
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.罗氟司特和吸入皮质类固醇/长效β2-激动剂对慢性阻塞性肺疾病加重的影响（RE(2)SPOND）。一项随机临床试验。
Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC.
6
Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators".用于慢性阻塞性肺疾病“超级加重期”的口服磷酸二酯酶-4抑制剂
Am J Respir Crit Care Med. 2016 Sep 1;194(5):527-8. doi: 10.1164/rccm.201608-1566ED.
7
Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中延长的急性加重期恢复的影响
Am J Respir Crit Care Med. 2015 Oct 15;192(8):943-50. doi: 10.1164/rccm.201412-2269OC.
8
Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.慢性阻塞性肺疾病（COPD）的住院加重：ECLIPSE队列中的危险因素及预后
Chest. 2015 Apr;147(4):999-1007. doi: 10.1378/chest.14-0655.
9
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.阿奇霉素维持治疗频繁加重的慢性阻塞性肺疾病（COLUMBUS）患者：一项随机、双盲、安慰剂对照试验。
Lancet Respir Med. 2014 May;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. Epub 2014 Apr 15.
10
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.基于验证性客观测量和全身炎症的慢性阻塞性肺疾病患者的共病群。
Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35. doi: 10.1164/rccm.201209-1665OC.
Zotero 插件